» Articles » PMID: 7641762

Late Effects of Anthracycline Therapy in Childhood in Relation to the Function of the Heart at Rest and Under Physical Stress

Overview
Journal Eur J Pediatr
Specialty Pediatrics
Date 1995 May 1
PMID 7641762
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

To evaluate the long-term effects of anthracyclines on the myocardium of the young child we examined 34 patients who had been treated with anthracyclines in childhood. In addition to anthracycline, the patients were treated with other potentially cardiotoxic substances within the framework of different protocols. The mean cumulative anthracycline dose was 128.6 mg/m2, the average age at onset of chemotherapy 4.2 years, and the time interval after discontinuation of treatment 9.0 years. The cardiological examination consisted of a physical examination, electrocardiography and echocardiography, including Doppler and bio-impedance cardiography. The patients were studied at rest and after physical exercise with a cycle ergometer test in a supine position. The results of the physical examination, the electrocardiogram at rest and the 24 h Holter monitoring were normal. The left ventricular enddiastolic diameter, shortening fraction, velocity of fibre shortening (VCF), the diastolic flow profile at the mitral valve level and the cardiac stroke volume at rest were also normal. However, the shortening fraction (SF) was below the margin of 2 standard deviations in two patients and the VCF in three patients. There was a significant reduction in septal thickness, (-1.4 SD, P < 0.0004), in the width of left ventricular posterior wall (-1.5 SD, P > 0.0002) and in the left ventricular myocardial mass (-0.76 SD, P = 0.0042). Physical working capacity was normal. Immediately after physical stress the expected rise of SF and VCF did not occur and the SF fell below the values at rest. In comparison to a healthy control group the SF and the VCF were markedly decreased (P > 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Exercise capacity in apparently healthy survivors of cancer.

De Caro E, Fioredda F, Calevo M, Smeraldi A, Saitta M, Hanau G Arch Dis Child. 2005; 91(1):47-51.

PMID: 16188959 PMC: 2083103. DOI: 10.1136/adc.2004.071241.

References
1.
Yeung S, Yoong C, Spink J, Galbraith A, Smith P . Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet. 1991; 337(8745):816-8. DOI: 10.1016/0140-6736(91)92516-5. View

2.
Goorin A, Chauvenet A, Perez-Atayde A, Cruz J, McKone R, Lipshultz S . Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr. 1990; 116(1):144-7. DOI: 10.1016/s0022-3476(05)81668-3. View

3.
Gottlieb S, Edmiston Jr W, Haywood L . Late, late doxorubicin cardiotoxicity. Chest. 1980; 78(6):880-2. DOI: 10.1378/chest.78.6.880. View

4.
Steinherz L, Steinherz P, Tan C, Heller G, Murphy M . Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991; 266(12):1672-7. View

5.
Colan S, Parness I, Spevak P, Sanders S . Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol. 1992; 19(3):619-29. DOI: 10.1016/s0735-1097(10)80282-7. View